Observational studyCancer medicine2025
Comparison of Disease Progression From Prostate Cancer Diagnosis to Metastatic or Nonmetastatic Castrate-Resistant Prostate Cancer (CRPC) Patients: CaPA Study.
Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundProstate cancer (PC) patients resistant to castration have decreased survival. Analysis of patient characteristics and disease management can contribute to new strategies to prevent or delay progression to castrate-resistant prostate cancer (CRPC). This study aimed to characterize and compare PC patients from initial PC diagnosis to metastatic CRPC (mCRPC) versus nonmetastatic (nmCRPC) stages in a real-world setting in Portugal.
methodsA multicenter, retrospective, non-interventional study was conducted across 18 Portuguese sites. Consenting adult patients (age ≥ 18 years) diagnosed with CRPC, either metastatic or nonmetastatic, were included in the study at the time of diagnosis or within 12 months of CRPC diagnosis.
resultsBetween November 2020 and December 2022, a total of 121 patients (73 mCRPC patients and 48 nmCRPC patients) were included. At diagnosis, the median age was 69.0 and 70.0 years in mCRPC and nmCRPC patients, respectively, and the most common histological subtype was acinar adenocarcinoma (mCRPC: 83.6%; nmCRPC: 91.7%). Significant differences were observed between the two groups regarding Eastern Cooperative Oncology Group Performance status (ECOG PS) (p = 0.023), Gleason score (p = 0.001), and American Joint Committee on Cancer (AJCC) stage (p < 0.001). The median time from PC diagnosis to first treatment and the treatments used prior to CRPC diagnosis were comparable between the groups. However, the median time from PC diagnosis to CRPC was significantly shorter in mCRPC versus nmCRPC patients (42.0 vs. 58.0 months, p = 0.006). Prostate-specific antigen (PSA) values were significantly higher in mCRPC than in nmCRPC patients at CRPC diagnosis (19.8 vs. 6.3 ng/mL; p < 0.001).
conclusionsThis real-world study showed that the time from initial PC diagnosis to castration resistance was significantly longer in nmCRPC than in mCRPC patients. The characteristics associated with a better prognosis at initial diagnosis and a better treatment response in nmCRPC patients might explain this difference in disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.